Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
—
62.71 M
About Statera Biopharma, Inc.
Sector
Industry
CEO
Michael Kevin Handley
Website
Headquarters
Fort Collins
Founded
2003
FIGI
BBG000C3YLS5
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of STAB is 0.0007 USD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Statera Biopharma, Inc. stocks are traded under the ticker STAB.
Statera Biopharma, Inc. is going to release the next earnings report on May 17, 2024. Keep track of upcoming events with our Earnings Calendar.
STAB stock is 0% volatile and has beta coefficient of 36.44 K. Check out the list of the most volatile stocks — is Statera Biopharma, Inc. there?
Yes, you can track Statera Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
STAB stock hasn't changed in a week, the month change is a 16.67% rise, over the last year Statera Biopharma, Inc. has showed a 96.60% decrease.
Today Statera Biopharma, Inc. has the market capitalization of 49.99 K, it has increased by 16.67% over the last week.
No, STAB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, STAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Statera Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Statera Biopharma, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Statera Biopharma, Inc. stock shows the sell signal. See more of Statera Biopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.